10.99 0.00 (0.00%)
After hours: 4:09PM EDT
|Bid||9.70 x 1800|
|Ask||11.26 x 1200|
|Day's Range||10.93 - 11.41|
|52 Week Range||8.45 - 50.75|
|Beta (3Y Monthly)||1.61|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.63|
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2019. Unless otherwise stated, all comparisons are for the second quarter 2019 compared to the second quarter of 2018.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on July 23, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 52,501 shares of Puma common stock to seven new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 8, 2019 following release of its second quarter 2019 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
LOS ANGELES-- -- Neratinib becomes the first anti-HER2 treatment to be approved in Canada, as extended adjuvant therapy for women with early stage HR-positive, HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved Health Canada indication resulted in a 51% reduction in the risk of invasive disease recurrence or death at 2 years versus placebo ...
MONTREAL, July 16, 2019 -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved.
Puma Biotechnology, Inc. , a biopharmaceutical company, presented updated interim results from the biliary cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019, currently taking place in Barcelona, Spain.
Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.
Puma Biotechnology, Inc. , a biopharmaceutical company, has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments .
The market's shortsightedness has it missing the long-term upside at this biotech, logistics specialist, and pipeline company.
If you own shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) then it's worth thinking about how it contributes to the...
Anyone researching Puma Biotechnology, Inc. (NASDAQ:PBYI) might want to consider the historical volatility of the...
Puma Biotechnology Inc NASDAQ/NGS:PBYIView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for PBYI with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PBYI are favorable, with net inflows of $2.33 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...